We are live on ! Find out more
Charles Schwab

Charles Schwab Portfolio holdings

AUM $654B
1-Year Est. Return 26.35%
 

Charles Schwab Corporation, founded in 1971 by Charles R. Schwab and headquartered in Westlake, Texas, is a leading financial services firm that revolutionized retail investing by offering low-cost brokerage services. Initially disrupting the industry with discount commissions, it has grown into a powerhouse providing a wide array of services, including trading platforms, robo-advisors, retirement accounts, and banking products, managing hundreds of billions in client assets. Known for its user-friendly technology and customer-centric approach, Schwab caters to individual investors, financial advisors, and institutions, notably expanding through its 2020 acquisition of TD Ameritrade. With a mission to democratize investing, Charles Schwab remains a dominant force in the shift toward accessible, self-directed wealth management.

This Fund
S&P 500
This Quarter Est. Return
+10.49%
1 Year Est. Return
+26.35%
3 Year Est. Return
+83.88%
5 Year Est. Return
+111.55%
10 Year Est. Return
+435.01%
AUM
$310B
AUM Growth
+$31.1B
Cap. Flow
+$9.23B
Cap. Flow %
2.98%
Top 10 Hldgs %
15.99%
Holding
3,632
New
124
Increased
2,654
Reduced
459
Closed
86

Sector Composition

Rank Sector Weight
1 Technology 19.49%
2 Financials 13.78%
3 Healthcare 13.39%
4 Industrials 9.54%
5 Consumer Discretionary 9.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
IMDX
3501
Insight Molecular Diagnostics
IMDX
$149M
$20K ﹤0.01%
3,114
ZYNE
3502
DELISTED
Zynerba Pharmaceuticals, Inc
ZYNE
$19.9K ﹤0.01%
37,596
GALT icon
3503
Galectin Therapeutics
GALT
$213M
$19.7K ﹤0.01%
17,413
FBIO icon
3504
Fortress Biotech
FBIO
$109M
$19.6K ﹤0.01%
1,998
ENZ
3505
DELISTED
Enzo Biochem, Inc.
ENZ
$19.3K ﹤0.01%
13,471
LPCN icon
3506
Lipocine
LPCN
$17.4M
$19.2K ﹤0.01%
2,941
SYBX
3507
DELISTED
Synlogic
SYBX
$19K ﹤0.01%
1,667
IZEA icon
3508
IZEA Worldwide
IZEA
$59.2M
$18.7K ﹤0.01%
8,622
BCLI
3509
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
$18.5K ﹤0.01%
752
VIRX
3510
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$18.1K ﹤0.01%
12,430
BFX
3511
DELISTED
BowFlex Inc.
BFX
$17.5K ﹤0.01%
11,457
INZY
3512
DELISTED
Inozyme Pharma
INZY
$17.4K ﹤0.01%
16,549
RCAT icon
3513
Red Cat Holdings
RCAT
$1.12B
$17.3K ﹤0.01%
18,398
INFI
3514
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$16.6K ﹤0.01%
29,948
QCLS
3515
Q/C Technologies Inc
QCLS
$21.3M
$16.1K ﹤0.01%
5
QUBT icon
3516
Quantum Computing Inc
QUBT
$1.81B
$15.4K ﹤0.01%
10,216
RVLP
3517
DELISTED
RVL Pharmaceuticals plc Ordinary Shares
RVLP
$14.9K ﹤0.01%
13,322
BOXL icon
3518
Boxlight
BOXL
$1.89M
$14.6K ﹤0.01%
33
TAST
3519
DELISTED
Carrols Restaurant Group, Inc.
TAST
$14.6K ﹤0.01%
10,728
CYPH
3520
Cypherpunk Technologies Inc
CYPH
$66.6M
$14.4K ﹤0.01%
3,200
NXTC icon
3521
NextCure
NXTC
$20.5M
$14.1K ﹤0.01%
833
BGXX
3522
DELISTED
Bright Green Corporation Common Stock
BGXX
$13.4K ﹤0.01%
28,510
ECOR icon
3523
electroCore
ECOR
$56.7M
$11.7K ﹤0.01%
3,035
-3
-0.1% -$14
TCDA
3524
DELISTED
Tricida, Inc. Common Stock
TCDA
$11.5K ﹤0.01%
74,893
-10,024
-12% -$29.8K
CRBP icon
3525
Corbus Pharmaceuticals
CRBP
$168M
$11K ﹤0.01%
3,314

Similar funds

Charles Schwab's Q4 2022 Portfolio in Review

As of Q4 2022, Charles Schwab held 3,632 positions worth $310B, up 11% from $279B the previous quarter. Its ten largest holdings account for 16% of the portfolio.

Charles Schwab's Q4 2022 filing shows 124 new, 2,654 increased, 459 reduced and 86 closed positions. Its largest new stake was iShares 0-5 Year TIPS Bond ETF: 4,612,793 shares worth $447M. The largest sale was Vanguard Intermediate-Term Treasury ETF, an estimated $738M.

By sector, the portfolio is most concentrated in Technology at 19% of assets, down from 20% a quarter earlier, followed by Financials and Healthcare.

  • Charles Schwab's largest Q4 2022 buy was iShares 0-5 Year TIPS Bond ETF: 4,612,793 shares worth $447M.
  • Charles Schwab added most to iShares 7-10 Year Treasury Bond ETF in Q4 2022, an estimated $1.04B increase.
  • Charles Schwab's biggest Q4 2022 reduction was Vanguard Intermediate-Term Treasury ETF, cutting an estimated $738M.
  • Charles Schwab fully exited Duke Realty Corp. in Q4 2022, selling an estimated $175M.
  • Charles Schwab's ten largest holdings make up 16% of its $310B portfolio in Q4 2022.
  • Charles Schwab opened 124 new positions and closed 86 in Q4 2022.
  • Charles Schwab's portfolio value rose 11% quarter-over-quarter to $310B.

Based on Charles Schwab's 13F filing for Q4 2022, filed 13 Feb 2023.